<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206422</article-id><article-id pub-id-type="doi">10.1101/2025.06.09.658569</article-id><article-id pub-id-type="archive">PPR1034664</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Selective targeting of IL-1RAP-dependent eosinophilic inflammation in allergic fungal airway disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Thomas J</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Griffiths</surname><given-names>James S</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gonzales-Huerta</surname><given-names>Luis E</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bell</surname><given-names>David</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Reed</surname><given-names>Anna K</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Anand</given-names></name></contrib><contrib contrib-type="author"><name><surname>Naglik</surname><given-names>Julian R</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Armstrong-James</surname><given-names>Darius</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Infectious Diseases, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>Department of Cardiothoracic Transplantation and Mechanical Support, Harefield Hospital, Royal Brompton &amp; Harefield Hospitals, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j161312</institution-id><institution>Guy’s and St Thomas’ NHS Foundation Trust</institution></institution-wrap>. <city>London</city>, <country country="GB">UK</country></aff><aff id="A3"><label>3</label>Centre for Host-Microbiome Interactions (CHMI), Faculty of Dentistry, Oral &amp; Craniofacial Sciences, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220mzb33</institution-id><institution>Kings College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A4"><label>4</label>Centre for Synthetic Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country>; SynbiCITE Innovation and Knowledge Centre, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/041kmwe10</institution-id><institution>Imperial College London</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><aff id="A5"><label>6</label>Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j161312</institution-id><institution>Guy’s and St Thomas’ NHS Foundation Trust</institution></institution-wrap>, <city>London</city>, <country country="GB">UK</country></aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author <email>d.armstrong@imperial.ac.uk</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>14</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>11</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">It is estimated that in excess of 10 million people around the globe are affected by severe asthma and fungal sensitisation (SAFS) or allergic bronchopulmonary aspergillosis (ABPA), severe asthma endotypes driven by hypersensitivity to environmentally ubiquitous fungal pathogens, primarily <italic>Aspergillus fumigatus</italic>. Here, we sought to define the immunological pathways underlying these allergic fungal airway diseases. To do so, we exploit the chronic exposure repeat challenge model using live <italic>A. fumigatus</italic> conidia to systematically define the key immunological pathways driving airway inflammation in allergic fungal airway disease. In response to daily intranasal challenge, we observed increased absolute numbers of neutrophils and eosinophils in bronchoalveolar lavage fluid (BALF), characteristic of human allergic fungal airway disease, with significant depletion of the alveolar macrophage population. Transcriptomic analysis of BALF cells identified increased expression of IL-1 family cytokines and receptors including IL-1β, IL-1RL1, IL-1R2 and the IL-18 binding protein. Complementary proteomic analysis of BALF revealed increased levels of cell death related proteins calprotectin and IL-1 Receptor Accessory Protein (IL-1RAP). Targeting IL-1RAP, using knockout mice, led to selective reduction in eosinophilia, IL-5 and IL-13 in the airways without impairment of fungal killing. This study identifies a role for IL-1RAP in the generation of eosinophilia independent of neutrophil influx and highlights its potential as a novel immunotherapeutic target for the treatment of allergic fungal airway disease.</p></abstract><kwd-group><kwd>Allergic Airway Disease</kwd><kwd><italic>Aspergillus fumigatus</italic></kwd><kwd>Eosinophilia</kwd><kwd>Repeat Challenge Mouse Model</kwd><kwd>IL-1 Receptor Accessory Protein</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">The opportunistic pathogen <italic>Aspergillus fumigatus (Af)</italic> is found ubiquitously in the air we breathe<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. Primary clinical presentations of <italic>Aspergillus</italic>-related disease complicating asthma are severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA)<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. The combined global burden of SAFS and ABPA is estimated to exceed 10 million people<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref>,<xref ref-type="bibr" rid="R5">5</xref></sup>. Long term ABPA may result in recurrent asthma exacerbations, steroid dependence, the development of bronchiectasis or pulmonary fibrosis, irreversible lung damage and the development of invasive disease<sup><xref ref-type="bibr" rid="R6">6</xref></sup>.</p><p id="P3">Commonly, murine models of allergic fungal airway disease are generated through sensitization of the mouse by intraperitoneal injection of <italic>Aspergillus</italic> extract with or without adjuvant<sup><xref ref-type="bibr" rid="R7">7</xref></sup>. This is followed by intranasal challenge with either <italic>Aspergillus</italic> extract or large doses of live <italic>Af</italic> conidia, however these models do not reflect the continuous human exposure to live conidia<sup><xref ref-type="bibr" rid="R8">8</xref></sup>. To address this issue models have been developed based on repeat or continuous airway exposure to live conidia<sup><xref ref-type="bibr" rid="R7">7</xref>,<xref ref-type="bibr" rid="R9">9</xref></sup>. These models have the additional benefit that they allow the true impact of immunotherapeutic interventions on both airway inflammation and control of fungal infection to be assessed.</p><p id="P4">IL-1 family members play an important role in the host response to infectious and immunological challenges. Two of the most well-known members of this family are IL-1α and IL-1β, highly inflammatory cytokines which when excessively released can lead to severe pathological consequences<sup><xref ref-type="bibr" rid="R10">10</xref></sup>. The cytokine IL-33 is another IL-1 family member that has been implicated in allergic airway inflammation <sup><xref ref-type="bibr" rid="R11">11</xref></sup>. Furthermore, fungal pathogens such as <italic>Af</italic> induce diverse programmed cell death responses in several immune cells, leading to the release of biologically active IL-1 family members<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>.</p><p id="P5">The IL-1 receptor family has been implicated in both cell death and allergy due to interactions with IL-1β and IL-33<sup><xref ref-type="bibr" rid="R14">14</xref></sup>. IL-1 receptor 1 (IL-1R1) forms a ternary complex with IL-1β and IL-1R accessory protein (IL-1RAP, also known as IL-1R3) resulting in NF-κB activation for a pro-inflammatory signal<sup><xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R16">16</xref></sup>. IL-1RAP can also form ternary complexes with other IL-1R family members such as with IL-1 Receptor-like 1 (IL-1RL1, also known as ST2) and IL-33, or IL-1RL2 and IL-36, leading to similar pro-inflammatory signals<sup><xref ref-type="bibr" rid="R17">17</xref>,<xref ref-type="bibr" rid="R18">18</xref></sup>. Given the involvement of these pathways in allergic airway diseases, these observations make it an attractive target for immunotherapy.</p><p id="P6">Combining transcriptomic and proteomic approaches we identified IL-1 family cytokines and receptors as central mediators of inflammatory signalling during experimental allergic fungal airway disease. Given the development of novel biologics targeting IL-1RAP<sup><xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup> we therefore investigated the impact of IL-1RAP deletion in this context. This led to selective reduction of eosinophil recruitment to the airway without increased fungal burden. Overall, we highlight a role for IL-1RAP in the eosinophilic response during allergic fungal airway disease suggesting that therapeutics targeting this receptor have potential for treating those with allergic fungal airway disease.</p></sec><sec id="S2" sec-type="methods"><title>Methods</title><sec id="S3"><title>Mouse Ethics and Housing</title><p id="P7">All mouse experiments were approved by the United Kingdom Home Office and the Imperial College animal ethics committee, performed in accordance with the project licenses PPL PF9534064 and PP6711863. Male C57BL/6J male mice (6-8 weeks old) were ordered from Charles River, UK. B6;129S1-Il1raptm1Roml/J (IL-1RAP<sup>-/-</sup>) were purchased from Jax (RRID:IMSR_JAX:003284) and backcrossed for 10 generations to C57BL/6J. All mice were housed in individually vented cages with free access to autoclaved food and water. Mice were assigned to experimental groups at random and, where possible, mixed among cages.</p></sec><sec id="S4"><title>Aspergillus culture</title><p id="P8"><italic>Aspergillus fumigatus</italic> strain CEA10 (FGSC A1163) was obtained from the Fungal Genetics Stock Centre, an eGFP-expressing strain (ATCC46645-eGFP) was kindly gifted from Frank Ebel. All strains were cultured on Sabouraud dextrose agar (Oxoid). Conidia were harvested in 0.1% Tween/H2O and filtered through MIRACLOTH (Calbiochem, UK).</p></sec><sec id="S5"><title>Repeat Challenge Aspergillus Model</title><p id="P9">Using the approach employed by Porter et al.<sup><xref ref-type="bibr" rid="R9">9</xref></sup>, mice were intranasally dosed with 2x10<sup>5</sup> resting conidia in 50μl of PBS while under isoflurane anaesthesia. Doses were repeated for 3, 7 and 14 days with mice being culled either 3 or 24 hours after the final dose by intra-peritoneal overdose of pentobarbital.</p></sec><sec id="S6"><title>Histology</title><p id="P10">Lungs were inflated, excised and fixed in 10% neutral buffered formalin overnight and moved into 70% ethanol. Lungs were then wax embedded, sectioned to 4μm sections and H&amp;E or PAS stained. %Inflammation and %Mucus were determined by threshold image analysis, using Image J software.</p></sec><sec id="S7"><title>Bronchoalveolar Lavage</title><p id="P11">Bronchoalveolar lavage (BAL) was performed by tracheal cut-down and intubation with a self-designed catheter. Lungs were lavaged by 3 separate instillations of 1ml of PBS/2mM EDTA. The supernatant fraction of the first instillation was used for LDH, Bradford, ELISA and Proteomics. The cell fractions of all 3 instillations were combined and used for flow cytometry. For CFUs all instillations were combined.</p></sec><sec id="S8"><title>Colony Forming Unit Assay</title><p id="P12">Serial dilution of BAL fluid was performed and plated onto Sabouraud dextrose agar plates in triplicate. Plates were incubated for 18-24 hrs at 37°C and CFUs were manually counted.</p></sec><sec id="S9"><title>Flow Cytometry</title><p id="P13">Cell pellets were stained according to the antibody details in Table 2.2 below, fixed in 2% formaldehyde (28908, ThermoFisher Scientific) and resuspended in FACS buffer (PBS, 1% FBS, 3mM EDTA). 123count eBeads counting beads (01-1234-42, ThermoFisher Scientific) were used for cell enumeration. For determination of GFP+ <italic>Af</italic> cells, CEA10 infected mice were used as threshold. Flow Cytometry was performed on an LSR Fortessa III flow cytometer (BD Biosciences). Data were analysed using FlowJo (Treestar).</p><table-wrap id="T1" orientation="portrait" position="anchor"><table frame="box" rules="all"><thead><tr><th valign="middle" align="center">Target<break/>Species</th><th valign="middle" align="center">Target<break/>Protein</th><th valign="middle" align="center">Fluorophore</th><th valign="middle" align="center">Clone</th><th valign="middle" align="center">Company</th><th valign="middle" align="center">Cat.<break/>Number</th></tr></thead><tbody><tr><td valign="middle" align="center" rowspan="12">Mouse</td><td valign="middle" align="center">Live/Dead</td><td valign="middle" align="center">Blue</td><td valign="middle" align="center">N/A</td><td valign="middle" align="center">Thermo Fisher Scientific</td><td valign="middle" align="center">L34959</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">CD19</td><td valign="middle" align="center">BV785</td><td valign="middle" align="center">6D5</td><td valign="middle" align="center">Biolegend</td><td valign="middle" align="center">115543</td></tr><tr><td valign="middle" align="center">CD45.2</td><td valign="middle" align="center">BUV737</td><td valign="middle" align="center">104</td><td valign="middle" align="center">BD</td><td valign="middle" align="center">564880</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">CD3</td><td valign="middle" align="center">BUV395</td><td valign="middle" align="center">17A2</td><td valign="middle" align="center">BD</td><td valign="middle" align="center">740268</td></tr><tr><td valign="middle" align="center">Ly6C</td><td valign="middle" align="center">PE Cy7</td><td valign="middle" align="center">HK1.4</td><td valign="middle" align="center">eBioscience</td><td valign="middle" align="center">25-5932-82</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">MHC-II-I/A<break/>I/E</td><td valign="middle" align="center">APC Cy7</td><td valign="middle" align="center">M5/114.15.2</td><td valign="middle" align="center">Biolegend</td><td valign="middle" align="center">107628</td></tr><tr><td valign="middle" align="center">Ly6G</td><td valign="middle" align="center">AF700</td><td valign="middle" align="center">1A8</td><td valign="middle" align="center">Biolegend</td><td valign="middle" align="center">127622</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">CD11b</td><td valign="middle" align="center">BV605</td><td valign="middle" align="center">M1/70</td><td valign="middle" align="center">Biolegend</td><td valign="middle" align="center">101237</td></tr><tr><td valign="middle" align="center">F4/80</td><td valign="middle" align="center">APC</td><td valign="middle" align="center">BM8</td><td valign="middle" align="center">Invitrogen</td><td valign="middle" align="center">17-4801-82</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">CD11c</td><td valign="middle" align="center">PE-Cy7</td><td valign="middle" align="center">HL3</td><td valign="middle" align="center">BD</td><td valign="middle" align="center">558079</td></tr><tr><td valign="middle" align="center">CD11c</td><td valign="middle" align="center">FITC</td><td valign="middle" align="center">HL3</td><td valign="middle" align="center">BD</td><td valign="middle" align="center">557400</td></tr><tr style="background-color:#F2F2F2"><td valign="middle" align="center">Siglec F</td><td valign="middle" align="center">PE</td><td valign="middle" align="center">E50-2440</td><td valign="middle" align="center">BD</td><td valign="middle" align="center">562068</td></tr></tbody></table></table-wrap></sec><sec id="S10"><title>Bradford Assay</title><p id="P14">Basic protein quantification of BAL supernatant was carried out using Pierce Coomassie Plus (Bradford) Assay Reagent (23238, ThermoFisher Scientific), concentrations were calculated based on a BSA standard curve.</p></sec><sec id="S11"><title>Transcriptomics</title><p id="P15">Bulk RNA was isolated from total bronchoalveolar lavage cells using QIAshredder (79654, Qiagen) and RNeasy Mini Kits (74104, Qiagen) according to the manufacturer’s instructions. RNA quantity and purity were assessed by Nanodrop. Sample integrity was checked using a BioAnlayzer (Agilent)</p><p id="P16">Library preparation was carried out by Novogene (Novogene (UK) Ltd). Messenger RNA was purified from total RNA using poly-T oligo-attached magnetic beads. After fragmentation, the first strand cDNA was synthesised using random hexamer primers, followed by the second strand cDNA synthesis using dTTP. The library was checked with Qubit and real-time PCR for quantification and Bioanlayzer for size distribution detection. Quantified libraries were pooled and sequenced on Illumina platforms.</p><p id="P17">Raw data (raw reads) of fastq format were firstly processed through fastp software. Clean data (clean reads) was obtained by removing reads containing adapter, reads containing ploy-N and low quality reads from raw data. Q20, Q30 and GC content of the clean data was calculated and all downstream analyses were based on the clean data with high quality.</p><p id="P18">Reads were mapped to the murine genome (GRCm39/mm39, GCF_000001635.27). An index of the reference genome was built using Hisat2 v2.05 and paired-end clean reads were aligned to the reference genome using Hisat v2.05. The mapped reads of each sample were assembled by StringTIe (v1.3.3b) in a reference-based approach.</p><p id="P19">Analysis of RNAseq libraries was carried out using the Qlucore Multiomics Explorer 3.9 (Qlucore, Sweden). This included determination of differentially expressed genes, volcano plot and heatmap generation. Genes with an adjusted P-value &lt;=0.05 and fold change &gt;2 were assigned as differentially expressed. Gene Ontology (GO) enrichment analysis – GO enrichment analysis was implemented by the clusterProfiler R package. GO terms with a corrected P-value &lt;=0.05 were considered significantly enriched by differentially expressed genes. The RNA-seq data generated during this study are available at NCBI Sequence Read Archive: PRJNA1250534.</p></sec><sec id="S12"><title>Proteomics</title><p id="P20">BAL supernatant was taken and spun down at 16000 g for 1 min in a 0.22 μm filter containing centrifuge tube. Undesirable proteins were removed from the samples using a Multiple Affinity Removal Spin Cartridge Mouse 3 (5188-5289, Agilent) according to the manufacturer’s instruction. Samples then underwent acetone precipitation, by addition of ice-cold acetone at a 1:5 ratio, at –80C for 1 hour. Precipitate pellets were dried, resuspended in a buffer containing 10mM TCEP, 40Mm Chloroacetamide, 1%SDC, 100mM tris-HCL P.H 8.8 and placed on a heat block at 95C for 10 mins. 0.5 μg Trypsin/LysC was added to the samples and left to digest overnight at room temperature, acetonitrile and TFA were added for final concentrations of 6% and 0.6% respectively. Samples were stored at -80 °C until analysis.</p><p id="P21">All samples were injected and separated on a 1290 liquid chromatography system (Agilent) operating in normal flow mode at 200 μl/minute. 10-20 μl of the sample was separated on a AdvanceBio Peptide Plus column (2.7 μm particle size, 2.1 i.d. x 50mm (Agilent)). A 19.5-minute method with the following gradient was used: 97% Buffer A (0.1% (v/v) formic acid in water), 3% Buffer B (0.1% (v/v) formic acid in acetonitrile). Buffer B was increased to 40% over 12.5 minutes, followed by an increase to 100% buffer B in 2 minutes, where it was held for 2 minutes. Buffer B was then ramped back down to 3% in 1 minute and equilibrated for 2 minutes prior to the next injection. The 1290 LC system was coupled to a 6550 iFunnel Q-ToF Mass Spectrometer (Agilent) equipped with an iFunnel electrospray source and running MassHunter Data Acquisition software.</p><p id="P22">For relative peptide abundance, data was acquired in MS only mode over the m/z range 300-1700 at the rate of 1 spectrum per second. Peptides were identified using an auto-MS/MS method selecting up to 20 precursors per cycle, with a threshold of 5000 counts and a charge state of 2 or greater. Profinder B10 (Agilent) was used for peak list generation. The resulting MS only files were imported into Mass Profiler Professional (Agilent) for relative peptide abundance comparison. Samples were grouped according to type and features (as defined by accurate mass and retention time) were clustered for further analysis. Results were filtered such that a feature was present in all samples within both groups. Log/log of the intensity of features in each sample group was plotted and a paired t-test (p &lt;0.05) was carried out to identify features that had a fold change of 2 or higher.</p><p id="P23">LC/MS/MS data was extracted into peak lists using SpectrumMill (Agilent). Database searching against SwissProt was achieved using the following search parameters; enzyme specificity: trypsin, charge states: 2 or greater, fixed modification: Cysteine carbaminoacetylation, and variable modifications: Methionine oxidised. A score of 11 was set for acceptance of peptide assignments and 19 for protein identifications as well as %SPI (the percentage of the extracted spectrum that is explained by the database search result) (&gt;60%).</p><p id="P24">Analysis of proteomic results was carried out using Qlucore Multiomics Explorer 3.9 (Qlucore, Sweden). This included determination of significantly different proteins, volcano plot and heatmap generation. Proteins with an adjusted P-value &lt;=0.05 were assigned as significant.</p><p id="P25">Functional protein association networks creation for the identified significant proteins was created using the STRING database and online platform (<ext-link ext-link-type="uri" xlink:href="https://string-db.org/">string-db.org</ext-link>). Clusters were created using MCL clustering (Inflation score &gt;4).</p></sec><sec id="S13"><title>Lactate Dehydrogenase (LDH) Assay</title><p id="P26">LDH levels in BAL supernatants were measured using the CytoTox 96® Non-Radioactive Cytotoxicity Assay kit (Promega) according to the manufacturer’s instructions.</p></sec><sec id="S14"><title>ELISA</title><p id="P27">ELISAs were performed according to the manufacturer’s instruction using the murine TNF-a, CXCL1, IL-1β, IL-33, IL-5 and IL-13 DuoSet kits from R&amp;D systems.</p></sec><sec id="S15"><title>Statistics</title><p id="P28">All data are expressed as mean ± SEM unless otherwise stated. To assess statistical significance, one-way ANOVA (≥3 groups), two-way ANOVA and Students t-test/Mann-Whitney test (2 groups) were carried out. For all figures, p values are represented as followed: *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, ****P&lt;0.0001. Statistical analyses were carried out using GraphPad Prism (La Jolla, CA, USA) or Qlucore Multiomics Explorer 3.9 (Qlucore, Sweden).</p></sec></sec><sec id="S16" sec-type="results"><title>Results</title><sec id="S17"><title>Chronic exposure to Af leads to increased inflammation, mucus production and fungal persistence in the lung</title><p id="P29">To elucidate the mechanisms of <italic>A. fumigatus</italic> eosinophilia in lung disease we first sought to establish repeat challenge models of allergic fungal airway disease for immune cell, transcriptomic and proteomic investigations. Using the approach employed by Porter <italic>et al</italic>.<sup><xref ref-type="bibr" rid="R9">9</xref></sup>, C57BL/6J were dosed intranasally for 14 days with 2x10<sup><xref ref-type="bibr" rid="R5">5</xref></sup> resting <italic>Af</italic> conidia (<xref ref-type="fig" rid="F1">Fig 1A</xref>). Mice were monitored for mortality and assessed for any signs of morbidity including weight loss, lethargy, and hunching. After 14 days of dosing the mortality rate was zero (<xref ref-type="fig" rid="F1">Fig 1B</xref>), and the <italic>Aspergillus</italic> exposed mice did not lose significant amounts of weight (<xref ref-type="fig" rid="F1">Fig 1C</xref>). H&amp;E staining demonstrated cellular infiltrates and inflammation of the airways of <italic>Af</italic> exposed mice (<xref ref-type="fig" rid="F1">Fig 1D</xref>), which was significantly increased on thresholding quantification (<xref ref-type="fig" rid="F1">Fig 1E</xref>). <italic>Af</italic> infected mice also exhibited mucus production that was not present in the PBS controls (<xref ref-type="fig" rid="F1">Fig 1F and G</xref>). On histological staining there was no clear evidence of <italic>Af</italic> conidia or hyphae present in the lungs, however CFU counts on bronchoalveolar lavage fluid (BALF) revealed low levels of <italic>Af</italic> in the airways (<xref ref-type="fig" rid="F1">Fig 1H</xref>), suggesting that whilst the majority of conidia are killed there is a low-level persistence of fungus in the airway.</p></sec><sec id="S18"><title>Chronic exposure to Af leads to eosinophilia and neutrophilia in the airways</title><p id="P30">We next sought to establish which cellular populations were present in the airways and how they changed over time in allergic fungal airway disease. Mice were culled 24 hours after having 3, 7 or 14 intranasal doses of <italic>Af</italic> and the cells in the BAL fluid were analysed by flow cytometry (<xref ref-type="fig" rid="F2">Fig 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S1</xref>). After 7 days of exposure, eosinophils represented ~40% of airway immune cells, increasing to ~75% after 14 days (<xref ref-type="fig" rid="F2">Fig 2B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2A</xref>). Significant influx of neutrophils occurred after 3 doses of <italic>Af</italic> (<xref ref-type="fig" rid="F2">Fig 2C</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2B</xref>). After 14 days of exposure, a significant reduction in the number of alveolar macrophages was observed (<xref ref-type="fig" rid="F2">Fig 2D</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2C</xref>). A significant infiltration of monocytes is seen after 3 days of exposure, increasing by day 7 (<xref ref-type="fig" rid="F2">Fig 2E</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2D</xref>). We observed significant increases in the number of T cells after 7 days of exposure which was increased again by day 14 (<xref ref-type="fig" rid="F2">Fig 2F</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2E</xref>), while B cells were significantly increased after 14 days (<xref ref-type="fig" rid="F2">Fig 2G</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S2F</xref>).</p><p id="P31">Approximately 1% of alveolar macrophages and 1.5% of neutrophils were in direct contact with <italic>Af</italic> conidia, highlighting their role as first lines of defence and primary phagocytes. We also observed a very small population, 0.05%, of eosinophils interacting directly with the conidia (<xref ref-type="supplementary-material" rid="SD1">Fig S2G and H</xref>).</p></sec><sec id="S19"><title>Chronic exposure to Af leads to cell death and increased levels IL-1 family cytokines and receptors</title><p id="P32">To systematically characterise the immune response during repeated <italic>Aspergillus</italic> exposure, we next carried out bulk transcriptomic analysis of the BAL cells. We identified 443 differentially expressed genes, of which 256 were upregulated and 187 were downregulated in mice exposed to <italic>Af</italic> for 14 days compared to PBS controls (<xref ref-type="fig" rid="F3">Fig 3A and B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1 and S2</xref>). Gene Ontology (GO) enrichment analysis showed upregulation of pathways expected during the generation of allergy including granulocyte migration, T cell activation and differentiation, and myeloid cell proliferation (<xref ref-type="fig" rid="F3">Fig 3C</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>), while downregulated pathways included autophagic pathways and nitric oxide biosynthesis/metabolism (<xref ref-type="fig" rid="F3">Fig 3D</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>). Investigating the differentially expressed genes at an individual level revealed several upregulated genes encoding for interleukins and interleukin receptors. These included the Type 2 cytokines IL-4 and IL-13, as well as receptors including IL-2 receptor beta unit (IL-2rb), IL-21 receptor (IL21r), IL-27 receptor alpha subunit (IL-27ra) and IL-20 receptor beta unit (IL-21rb). Genes encoding the IL-1 family signalling members IL-1 receptor-like 1 (IL-1rl1/ST2), IL-1 receptor 2 (IL-1r2), IL-1β and IL-18 binding protein (IL-18bp) were also significantly upregulated during repeat fungal challenge (<xref ref-type="fig" rid="F3">Fig 3E</xref>).</p><p id="P33">Having observed increased expression of IL-1 family cytokines and receptors we further characterised the BALF to investigate the amount of inflammatory cell death occurring in the airway. As a proxy of inflammatory cell death, we measured the levels of lactate dehydrogenase (LDH) and free protein in the airways. At 14 days there was a significant increase in the levels of both LDH and free protein in the exposed mice (<xref ref-type="fig" rid="F4">Fig 4A and B</xref>). To complement our transcriptomic results, we undertook proteomic analysis of the BALF identifying 164 proteins. Of these 164 proteins, 42 were differentially expressed, 38 increased and 4 decreased, in <italic>Af treated</italic> mice compared to PBS controls (<xref ref-type="fig" rid="F4">Fig 4C and D</xref>) (<xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). These proteins included the classic DAMP calprotectin (S100A8/S100A9) and the IL-1 family signalling co-receptor IL-1 receptor accessory protein (IL-1RAP) as well as complement proteins, chitinases and pulmonary surfactants. Having further evidence of IL-1 family signalling by the identification of IL-1RAP, we examined the levels of the IL-1 family cytokines that signal through IL-1RAP, IL-1β and IL-33. We observed significant increases in the levels of both IL-1β and IL-33 in the BALF of mice exposed to <italic>Af</italic> for 14 days (<xref ref-type="fig" rid="F4">Fig 4E-G</xref>). This, taken together with the increased levels of LDH and upregulation of IL-1 family receptors, suggests that inflammatory cell death is occurring in the airways of mice with allergic fungal airway disease followed by the release and subsequent signalling of IL-1 cytokines through receptor complexes containing IL-1RAP.</p></sec><sec id="S20"><title>IL-1RAP mediates eosinophilic inflammation during chronic exposure to Af</title><p id="P34">IL-1RAP is a key co-receptor in the IL-1 family signalling pathway, acting as a co-receptor for IL-1r1 which binds IL-1α and IL-1β, for IL-1rl1 (ST2) which binds IL-33 and for IL-1rl2 (IL-36r) which binds IL-36, making it essential for effective IL-1 family signalling. Having identified increased levels of IL-1β and IL-33, upregulation of IL-1rL1 and increased levels of IL-1RAP in the airways, we next sought to investigate the role that IL-1RAP plays in the generation of allergic fungal airway disease using IL-1RAP knockout mice (IL-1RAP<sup>-/-</sup>). No mortality or significant weight loss were observed in the IL-1RAP<sup>-/-</sup> mice compared to wildtype (WT) controls during allergic fungal airway disease (<xref ref-type="fig" rid="F5">Fig 5A</xref>). We observed a significant reduction in the number of eosinophils in the airways of IL-1RAP<sup>-/-</sup> mice compared to WT controls (<xref ref-type="fig" rid="F5">Fig 5B</xref>). However, no significant difference was observed in the number of alveolar macrophages or neutrophils (<xref ref-type="fig" rid="F5">Fig 5C and D</xref>). Additionally, we found no significant difference in fungal control between IL-1RAP<sup>-/-</sup> mice and WT controls (<xref ref-type="fig" rid="F5">Fig 5E</xref>). Finally, having observed reduction in the eosinophil numbers in the airway, we measured levels of IL-33, IL-5 and IL-13, cytokines typically associated with the allergic response and eosinophil chemotaxis. We did not observe any difference in airway levels of IL-33 (<xref ref-type="fig" rid="F5">Fig 5F</xref>), however there were significant reductions in the amounts of both IL-5 and IL-13 (<xref ref-type="fig" rid="F5">Fig 5G</xref> and H). This suggests that deficiency in IL-1RAP results in reduced eosinophilia due to reduced levels of the downstream eosinophil chemoattractants IL-5 and IL-13, likely as a result of the inability to signal through the IL-33/IL-1RL1/IL-1RAP signalling axis.</p></sec></sec><sec id="S21" sec-type="discussion"><title>Discussion</title><p id="P35">ABPA is characterised by recurrent inflammatory exacerbations leading to lung damage and eventual decline. Here, we present a systematic characterisation of the inflammatory response in the murine model of allergic fungal airway disease through a multi-omic approach. Using knockout animals, we investigated the role that IL-1RAP plays in the generation of allergic fungal airway disease.</p><p id="P36">Allergic fungal airway disease is typically characterised by airway eosinophilia, increased IgE levels, increased T cell responses and inflammation of the airways<sup><xref ref-type="bibr" rid="R22">22</xref></sup>. We observe that the repeat challenge model of allergic fungal airway disease phenocopies immunological features of human allergic fungal airway disease such as sustained eosinophil and neutrophil influx, alveolar macrophage loss. These observations were associated with increased levels of cell death and damage markers. Although the source of these markers has not yet been characterised, they are likely a combination of damaged epithelia, dying alveolar macrophages and extracellular trap releasing granulocytes.</p><p id="P37"><italic>Af</italic> is known to cause significant damage to the epithelium during infection, resulting in the release of inflammatory mediators including IL-1α, IL-33, HMGB1, and TSLP<sup><xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R28">28</xref></sup>. In this model, repeat dosing of <italic>Af</italic> conidia represents a constant assault on the epithelium likely leading to significant epithelial damage. The loss of alveolar macrophages together with increased LDH and IL-1β levels is also indicative of cell death. While <italic>Af</italic> can lyse cells, through the process of germination<sup><xref ref-type="bibr" rid="R29">29</xref></sup>, the lack of any evidence of fungal hyphae by histology suggests that fungal spores are being controlled. Therefore, any <italic>Af</italic>-induced death is likely to be a result of programmed cell death pathways, for which <italic>Af</italic> can induce a broad range of types<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>. Extracellular trap release from neutrophils and eosinophils may also contribute the inflammatory profile seen in this model. Neutrophil extracellular traps (NETs) are known to be released in response to <italic>Af</italic> while eosinophil extracellular traps (EETs) have been shown to be present in the sputum of those with ABPA<sup><xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R35">35</xref></sup>. While these ETs restrict hyphal growth, they do not contribute to killing of the fungus and their unrestricted release is considered pathogenic<sup><xref ref-type="bibr" rid="R36">36</xref>–<xref ref-type="bibr" rid="R38">38</xref></sup>. Transcriptomics of airway cells corroborated with plate-based assays identified increased expression and levels of cell death and damage markers including LDH, IL-1α, IL-1β, and IL-33, as well as upregulation of IL-1 family receptor IL-1RL1, in the airways of mice with allergic fungal airway disease.</p><p id="P38">Proteomic analysis of BAL fluid showed significantly increased levels of chitinase-3 like protein 1 (CHI3L1) and acidic mammalian chitinase (AMCase). CHI3L1 is a known contributor to allergy by contributing to M2 macrophage polarisation and Th2 induction in both skin and food allergies, with polymorphisms in CHI3L1 associated with the development of bronchial asthma and airway remodelling<sup><xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref></sup>. AMCase has demonstrated antifungal properties, targeting of chitin in the fungal cell wall<sup><xref ref-type="bibr" rid="R42">42</xref>,<xref ref-type="bibr" rid="R43">43</xref></sup>. Studies have shown that chitin induces the recruitment of IL-4 expressing immune cells to the lung facilitating allergic inflammation, this was abrogated with exogenous AMCase treatment or overexpression of AMCase in a murine model<sup><xref ref-type="bibr" rid="R44">44</xref>,<xref ref-type="bibr" rid="R45">45</xref></sup>. AMCase has also been implicated in the pathology of allergy<sup><xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R46">46</xref></sup>, it was shown that neutralisation of AMCase ameliorated Th2 dependent inflammation and airway hyperreactivity by inhibiting the IL-13 response<sup><xref ref-type="bibr" rid="R47">47</xref></sup>.</p><p id="P39">Moreover, the proteomic analysis of the BAL from mice with allergic fungal airway disease also supports ongoing cell death in the airway with the detection of S100A8 and S100A9 which form the heterodimer calprotectin, a well-established DAMP related to inflammatory cell death and a common marker of tissue inflammation<sup><xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R51">51</xref></sup>. Lastly and of interest, along with increases in the IL-1 family members IL-33 and IL-1RL1 receptor, IL-1RAP was found to be significantly increased in the airways of mice with allergic fungal airway disease. IL-1RAP is an essential co-receptor for IL-1 family signalling, in this context primarily for IL-1β and IL-33 signalling and therefore represents an attractive target for immunotherapeutic intervention. Of note, increased expression of IL-1RAP and IL-33 activation have previously been associated with severe neutrophilic asthma<sup><xref ref-type="bibr" rid="R52">52</xref></sup>.</p><p id="P40">Similar to previous studies investigating the role of IL-33 signalling in allergy, in which IL-1RL1 (ST2) knockout mice showed reduced eosinophilia during allergen challenge<sup><xref ref-type="bibr" rid="R53">53</xref></sup> IL-1RAP<sup>-/-</sup> mice with allergic fungal airway disease demonstrated selective reduction of eosinophilia and reduced production of IL-5 and IL-13. The mechanistic basis for these observations is further delineated by the observation that IL-33 challenged IL-1RAP<sup>-/-</sup> mice also showed reduced eosinophilia and IL-5<sup><xref ref-type="bibr" rid="R54">54</xref></sup>. The primary producers of these cytokines during allergy are Th2, ILC2 and mast cells signalling through the IL-1RL1/IL-33 axis<sup><xref ref-type="bibr" rid="R55">55</xref>–<xref ref-type="bibr" rid="R57">57</xref></sup>.</p><p id="P41">Taken together, these observations suggest that IL-1RAP is required for IL-33/IL-1RL1-dependent signalling, IL-5 and IL-13 production and subsequently eosinophilia in allergic fungal airway disease. Monoclonal antibodies targeting IL-1RAP as a pan-IL1 family blockade therapy have been shown to reduce inflammation in murine models of sterile inflammation and are currently undergoing clinical trials<sup><xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup>. Our observations identify IL-1RAP as a novel immunotherapeutically-tractable inflammatory mediator that has potential for selective targeting of eosinophilic inflammation in ABPA.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS206422-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d26aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Funding</title><p>T.J.W. and D.A-J. were supported by funding from the Cystic Fibrosis Trust (grant no. SRC015 and THUB02). J.R.N was supported by grants from the Wellcome Trust (214229_Z_18_Z) and National Institutes of Health (DE022550).</p></ack><ref-list><ref id="R1"><label>(1)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latge</surname><given-names>JP</given-names></name></person-group><article-title>Aspergillus fumigatus and aspergillosis</article-title><source>Clinical microbiology reviews</source><year>1999</year><volume>12</volume><issue>2</issue><fpage>310</fpage><lpage>350</lpage><pub-id pub-id-type="pmcid">PMC88920</pub-id><pub-id pub-id-type="pmid">10194462</pub-id><pub-id pub-id-type="doi">10.1128/cmr.12.2.310</pub-id></element-citation></ref><ref id="R2"><label>(2)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Panjabi</surname><given-names>C</given-names></name></person-group><article-title>Allergic aspergillosis of the respiratory tract</article-title><source>European respiratory review : an official journal of the European Respiratory Society</source><year>2014</year><volume>23</volume><issue>131</issue><fpage>8</fpage><lpage>29</lpage><pub-id pub-id-type="pmcid">PMC9487274</pub-id><pub-id pub-id-type="pmid">24591658</pub-id><pub-id pub-id-type="doi">10.1183/09059180.00007413</pub-id></element-citation></ref><ref id="R3"><label>(3)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denning</surname><given-names>DW</given-names></name><name><surname>Pleuvry</surname><given-names>A</given-names></name><name><surname>Cole</surname><given-names>DC</given-names></name></person-group><article-title>Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults</article-title><source>Medical mycology</source><year>2013</year><volume>51</volume><issue>4</issue><fpage>361</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">23210682</pub-id></element-citation></ref><ref id="R4"><label>(4)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Chakrabarti</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Guleria</surname><given-names>R</given-names></name><etal/></person-group><article-title>Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria</article-title><source>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</source><year>2013</year><volume>43</volume><issue>8</issue><fpage>850</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">23889240</pub-id></element-citation></ref><ref id="R5"><label>(5)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denning</surname><given-names>DW</given-names></name><name><surname>Pfavayi</surname><given-names>LT</given-names></name></person-group><article-title>Poorly controlled asthma - Easy wins and future prospects for addressing fungal allergy</article-title><source>Allergology international : official journal of the Japanese Society of Allergology</source><year>2023</year><volume>72</volume><issue>4</issue><fpage>493</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">37544851</pub-id></element-citation></ref><ref id="R6"><label>(6)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewington-Gower</surname><given-names>E</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name></person-group><article-title>Review of current and future therapeutics in ABPA</article-title><source>Therapeutic advances in chronic disease</source><year>2021</year><volume>12</volume><elocation-id>2040.22.21.047003</elocation-id><pub-id pub-id-type="pmcid">PMC8543630</pub-id><pub-id pub-id-type="pmid">34729149</pub-id><pub-id pub-id-type="doi">10.1177/20406223211047003</pub-id></element-citation></ref><ref id="R7"><label>(7)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nials</surname><given-names>AT</given-names></name><name><surname>Uddin</surname><given-names>S</given-names></name></person-group><article-title>Mouse models of allergic asthma: acute and chronic allergen challenge</article-title><source>Disease models &amp; mechanisms</source><year>2008</year><volume>1</volume><issue>4-5</issue><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="pmcid">PMC2590830</pub-id><pub-id pub-id-type="pmid">19093027</pub-id><pub-id pub-id-type="doi">10.1242/dmm.000323</pub-id></element-citation></ref><ref id="R8"><label>(8)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres-Borrego</surname><given-names>J</given-names></name><name><surname>Sanchez-Solis</surname><given-names>M</given-names></name></person-group><article-title>Dissecting Airborne Allergens</article-title><source>Journal of clinical medicine</source><year>2023</year><volume>12</volume><issue>18</issue><fpage>5856</fpage><pub-id pub-id-type="pmcid">PMC10532401</pub-id><pub-id pub-id-type="pmid">37762797</pub-id><pub-id pub-id-type="doi">10.3390/jcm12185856</pub-id></element-citation></ref><ref id="R9"><label>(9)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>PC</given-names></name><name><surname>Roberts</surname><given-names>L</given-names></name><name><surname>Fields</surname><given-names>A</given-names></name><name><surname>Knight</surname><given-names>M</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Delclos</surname><given-names>GL</given-names></name><etal/></person-group><article-title>Necessary and sufficient role for T helper cells to prevent fungal dissemination in allergic lung disease</article-title><source>Infection and immunity</source><year>2011</year><volume>79</volume><issue>11</issue><fpage>4459</fpage><lpage>4471</lpage><pub-id pub-id-type="pmcid">PMC3257943</pub-id><pub-id pub-id-type="pmid">21875960</pub-id><pub-id pub-id-type="doi">10.1128/IAI.05209-11</pub-id></element-citation></ref><ref id="R10"><label>(10)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gasse</surname><given-names>P</given-names></name><name><surname>Mary</surname><given-names>C</given-names></name><name><surname>Guenon</surname><given-names>I</given-names></name><name><surname>Noulin</surname><given-names>N</given-names></name><name><surname>Charron</surname><given-names>S</given-names></name><name><surname>Schnyder-Candrian</surname><given-names>S</given-names></name><etal/></person-group><article-title>IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice</article-title><source>The Journal of clinical investigation</source><year>2007</year><volume>117</volume><issue>12</issue><fpage>3786</fpage><lpage>3799</lpage><pub-id pub-id-type="pmcid">PMC2066195</pub-id><pub-id pub-id-type="pmid">17992263</pub-id><pub-id pub-id-type="doi">10.1172/JCI32285</pub-id></element-citation></ref><ref id="R11"><label>(11)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makrinioti</surname><given-names>H</given-names></name><name><surname>Toussaint</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>DJ</given-names></name><name><surname>Walton</surname><given-names>RP</given-names></name><name><surname>Johnston</surname><given-names>SL</given-names></name></person-group><article-title>Role of interleukin 33 in respiratory allergy and asthma</article-title><source>The LancetRespiratory medicine</source><year>2014</year><volume>2</volume><issue>3</issue><fpage>226</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">24621684</pub-id></element-citation></ref><ref id="R12"><label>(12)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>TJ</given-names></name><name><surname>Gonzales-Huerta</surname><given-names>LE</given-names></name><name><surname>Armstrong-James</surname><given-names>D</given-names></name></person-group><article-title>Fungal-Induced Programmed Cell Death</article-title><source>Journal of fungi (Basel, Switzerland)</source><year>2021</year><volume>7</volume><issue>3</issue><fpage>231</fpage><comment>10.3390/jof7030231</comment><pub-id pub-id-type="pmcid">PMC8003624</pub-id><pub-id pub-id-type="pmid">33804601</pub-id><pub-id pub-id-type="doi">10.3390/jof7030231</pub-id></element-citation></ref><ref id="R13"><label>(13)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilli</surname><given-names>G</given-names></name><name><surname>Blagojevic</surname><given-names>M</given-names></name><name><surname>Naglik</surname><given-names>JR</given-names></name><name><surname>Richardson</surname><given-names>JP</given-names></name></person-group><article-title>Programmed Cell Death: Central Player in Fungal Infections</article-title><source>Trends in cell biology</source><year>2021</year><volume>31</volume><issue>3</issue><fpage>179</fpage><lpage>196</lpage><pub-id pub-id-type="pmcid">PMC7880884</pub-id><pub-id pub-id-type="pmid">33293167</pub-id><pub-id pub-id-type="doi">10.1016/j.tcb.2020.11.005</pub-id></element-citation></ref><ref id="R14"><label>(14)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>Overview of the IL-1 family in innate inflammation and acquired immunity</article-title><source>Immunological reviews</source><year>2018</year><volume>281</volume><issue>1</issue><fpage>8</fpage><lpage>27</lpage><pub-id pub-id-type="pmcid">PMC5756628</pub-id><pub-id pub-id-type="pmid">29247995</pub-id><pub-id pub-id-type="doi">10.1111/imr.12621</pub-id></element-citation></ref><ref id="R15"><label>(15)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Bazan</surname><given-names>JF</given-names></name><name><surname>Garcia</surname><given-names>KC</given-names></name></person-group><article-title>Structure of the activating IL-1 receptor signaling complex</article-title><source>Nature structural &amp; molecular biology</source><year>2012</year><volume>19</volume><issue>4</issue><fpage>455</fpage><lpage>457</lpage><pub-id pub-id-type="pmcid">PMC4006550</pub-id><pub-id pub-id-type="pmid">22426547</pub-id><pub-id pub-id-type="doi">10.1038/nsmb.2260</pub-id></element-citation></ref><ref id="R16"><label>(16)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balahura</surname><given-names>LR</given-names></name><name><surname>Selaru</surname><given-names>A</given-names></name><name><surname>Dinescu</surname><given-names>S</given-names></name><name><surname>Costache</surname><given-names>M</given-names></name></person-group><article-title>Inflammation and Inflammasomes: Pros and Cons in Tumorigenesis</article-title><source>Journal of immunology research</source><year>2020</year><volume>2020</volume><elocation-id>2549763</elocation-id><pub-id pub-id-type="pmcid">PMC7520695</pub-id><pub-id pub-id-type="pmid">33015196</pub-id><pub-id pub-id-type="doi">10.1155/2020/2549763</pub-id></element-citation></ref><ref id="R17"><label>(17)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingel</surname><given-names>A</given-names></name><name><surname>Weiss</surname><given-names>TM</given-names></name><name><surname>Niebuhr</surname><given-names>M</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>Appleton</surname><given-names>BA</given-names></name><name><surname>Wiesmann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Structure of IL-33 and its interaction with the ST2 and IL-1RAcP receptors--insight into heterotrimeric IL-1 signaling complexes</article-title><source>Structure (London, England : 1993)</source><year>2009</year><volume>17</volume><issue>10</issue><fpage>1398</fpage><lpage>1410</lpage><pub-id pub-id-type="pmcid">PMC2766095</pub-id><pub-id pub-id-type="pmid">19836339</pub-id><pub-id pub-id-type="doi">10.1016/j.str.2009.08.009</pub-id></element-citation></ref><ref id="R18"><label>(18)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Queen</surname><given-names>D</given-names></name><name><surname>Ediriweera</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group><article-title>Function and Regulation of IL-36 Signaling in Inflammatory Diseases and Cancer Development</article-title><source>Frontiers in cell and developmental biology</source><year>2019</year><volume>7</volume><fpage>317</fpage><pub-id pub-id-type="pmcid">PMC6904269</pub-id><pub-id pub-id-type="pmid">31867327</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2019.00317</pub-id></element-citation></ref><ref id="R19"><label>(19)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantargia</surname><given-names>AB</given-names></name></person-group><article-title>A Phase I (First-in-human) Randomized, Double-blind, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects With Mild to Moderate Plaque Psoriasis</article-title><year>2023</year></element-citation></ref><ref id="R20"><label>(20)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gronberg</surname><given-names>C</given-names></name><name><surname>Rattik</surname><given-names>S</given-names></name><name><surname>Tran-Manh</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Rius Rigau</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis</article-title><source>Annals of the Rheumatic Diseases</source><year>2024</year><volume>83</volume><issue>9</issue><fpage>1156</fpage><lpage>1168</lpage><pub-id pub-id-type="pmcid">PMC11420747</pub-id><pub-id pub-id-type="pmid">38594058</pub-id><pub-id pub-id-type="doi">10.1136/ard-2023-225158</pub-id></element-citation></ref><ref id="R21"><label>(21)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fields</surname><given-names>JK</given-names></name><name><surname>Gyllenback</surname><given-names>EJ</given-names></name><name><surname>Bogacz</surname><given-names>M</given-names></name><name><surname>Obi</surname><given-names>J</given-names></name><name><surname>Birkedal</surname><given-names>GS</given-names></name><name><surname>Sjostrom</surname><given-names>K</given-names></name><etal/></person-group><article-title>Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling</article-title><source>Cell reports</source><year>2024</year><volume>43</volume><issue>5</issue><elocation-id>114099</elocation-id><pub-id pub-id-type="pmcid">PMC11587196</pub-id><pub-id pub-id-type="pmid">38636519</pub-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114099</pub-id></element-citation></ref><ref id="R22"><label>(22)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutsen</surname><given-names>AP</given-names></name><name><surname>Slavin</surname><given-names>RG</given-names></name></person-group><article-title>Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis</article-title><source>Clinical &amp; developmental immunology</source><year>2011</year><volume>2011</volume><elocation-id>843763</elocation-id><pub-id pub-id-type="pmcid">PMC3095475</pub-id><pub-id pub-id-type="pmid">21603163</pub-id><pub-id pub-id-type="doi">10.1155/2011/843763</pub-id></element-citation></ref><ref id="R23"><label>(23)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravelat</surname><given-names>FN</given-names></name><name><surname>Beauvais</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Snarr</surname><given-names>BD</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal beta-glucan from the immune system</article-title><source>PLoS pathogens</source><year>2013</year><volume>9</volume><issue>8</issue><elocation-id>e1003575</elocation-id><pub-id pub-id-type="pmcid">PMC3749958</pub-id><pub-id pub-id-type="pmid">23990787</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003575</pub-id></element-citation></ref><ref id="R24"><label>(24)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertuzzi</surname><given-names>M</given-names></name><name><surname>Schrettl</surname><given-names>M</given-names></name><name><surname>Alcazar-Fuoli</surname><given-names>L</given-names></name><name><surname>Cairns</surname><given-names>TC</given-names></name><name><surname>Munoz</surname><given-names>A</given-names></name><name><surname>Walker</surname><given-names>LA</given-names></name><etal/></person-group><article-title>The pH-responsive PacC transcription factor of Aspergillus fumigatus governs epithelial entry and tissue invasion during pulmonary aspergillosis</article-title><source>PLoS pathogens</source><year>2014</year><volume>10</volume><issue>10</issue><elocation-id>e1004413</elocation-id><pub-id pub-id-type="pmcid">PMC4199764</pub-id><pub-id pub-id-type="pmid">25329394</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004413</pub-id></element-citation></ref><ref id="R25"><label>(25)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okaa</surname><given-names>UJ</given-names></name><name><surname>Bertuzzi</surname><given-names>M</given-names></name><name><surname>Fortune-Grant</surname><given-names>R</given-names></name><name><surname>Thomson</surname><given-names>DD</given-names></name><name><surname>Moyes</surname><given-names>DL</given-names></name><name><surname>Naglik</surname><given-names>JR</given-names></name><etal/></person-group><article-title>Aspergillus fumigatus Drives Tissue Damage via Iterative Assaults upon Mucosal Integrity and Immune Homeostasis</article-title><source>Infection and immunity</source><year>2023</year><volume>91</volume><issue>2</issue><fpage>e0033322</fpage><lpage>22</lpage><comment>Epub 2023 Jan 10</comment><pub-id pub-id-type="pmcid">PMC9933693</pub-id><pub-id pub-id-type="pmid">36625602</pub-id><pub-id pub-id-type="doi">10.1128/iai.00333-22</pub-id></element-citation></ref><ref id="R26"><label>(26)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraishi</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>S</given-names></name><name><surname>Yoshizaki</surname><given-names>T</given-names></name><name><surname>Nambu</surname><given-names>A</given-names></name><name><surname>Shimura</surname><given-names>E</given-names></name><name><surname>Takamori</surname><given-names>A</given-names></name><etal/></person-group><article-title>IL-33, IL-25 and TSLP contribute to development of fungal-associated protease-induced innate-type airway inflammation</article-title><source>Scientific reports</source><year>2018</year><volume>8</volume><issue>1</issue><elocation-id>18052–x</elocation-id><pub-id pub-id-type="pmcid">PMC6303299</pub-id><pub-id pub-id-type="pmid">30575775</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-36440-x</pub-id></element-citation></ref><ref id="R27"><label>(27)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharon</surname><given-names>H</given-names></name><name><surname>Amar</surname><given-names>D</given-names></name><name><surname>Levdansky</surname><given-names>E</given-names></name><name><surname>Mircus</surname><given-names>G</given-names></name><name><surname>Shadkchan</surname><given-names>Y</given-names></name><name><surname>Shamir</surname><given-names>R</given-names></name><etal/></person-group><article-title>PrtT-regulated proteins secreted by Aspergillus fumigatus activate MAPK signaling in exposed A549 lung cells leading to necrotic cell death</article-title><source>PloS one</source><year>2011</year><volume>6</volume><issue>3</issue><elocation-id>e17509</elocation-id><pub-id pub-id-type="pmcid">PMC3055868</pub-id><pub-id pub-id-type="pmid">21412410</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0017509</pub-id></element-citation></ref><ref id="R28"><label>(28)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrecht</surname><given-names>BN</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name></person-group><article-title>Allergens and the airway epithelium response: gateway to allergic sensitization</article-title><source>The Journal of allergy and clinical immunology</source><year>2014</year><volume>134</volume><issue>3</issue><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="pmid">25171864</pub-id></element-citation></ref><ref id="R29"><label>(29)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Waeyenberghe</surname><given-names>L</given-names></name><name><surname>Pasmans</surname><given-names>F</given-names></name><name><surname>D’Herde</surname><given-names>K</given-names></name><name><surname>Ducatelle</surname><given-names>R</given-names></name><name><surname>Favoreel</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>Germination of Aspergillus fumigatus inside avian respiratory macrophages is associated with cytotoxicity</article-title><source>Veterinary research</source><year>2012</year><volume>43</volume><issue>1</issue><comment>32-32</comment><pub-id pub-id-type="pmcid">PMC3414738</pub-id><pub-id pub-id-type="pmid">22515231</pub-id><pub-id pub-id-type="doi">10.1186/1297-9716-43-32</pub-id></element-citation></ref><ref id="R30"><label>(30)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Man</surname><given-names>SM</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Gurung</surname><given-names>P</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Lamkanfi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Concerted activation of the AIM2 and NLRP3 inflammasomes orchestrates host protection against Aspergillus infection</article-title><source>Cell host &amp; microbe</source><year>2015</year><volume>17</volume><issue>3</issue><fpage>357</fpage><lpage>368</lpage><pub-id pub-id-type="pmcid">PMC4359672</pub-id><pub-id pub-id-type="pmid">25704009</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2015.01.006</pub-id></element-citation></ref><ref id="R31"><label>(31)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shlomovitz</surname><given-names>I</given-names></name><name><surname>Erlich</surname><given-names>Z</given-names></name><name><surname>Speir</surname><given-names>M</given-names></name><name><surname>Zargarian</surname><given-names>S</given-names></name><name><surname>Baram</surname><given-names>N</given-names></name><name><surname>Engler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Necroptosis directly induces the release of full-length biologically active IL-33 in vitro and in an inflammatory disease model</article-title><source>The FEBS journal</source><year>2019</year><volume>286</volume><issue>3</issue><fpage>507</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">30576068</pub-id></element-citation></ref><ref id="R32"><label>(32)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueki</surname><given-names>S</given-names></name><name><surname>Hebisawa</surname><given-names>A</given-names></name><name><surname>Kitani</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Neves</surname><given-names>JS</given-names></name></person-group><article-title>Allergic Bronchopulmonary Aspergillosis-A Luminal Hypereosinophilic Disease With Extracellular Trap Cell Death</article-title><source>Frontiers in immunology</source><year>2018</year><volume>9</volume><fpage>2346</fpage><pub-id pub-id-type="pmcid">PMC6193060</pub-id><pub-id pub-id-type="pmid">30364279</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02346</pub-id></element-citation></ref><ref id="R33"><label>(33)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omokawa</surname><given-names>A</given-names></name><name><surname>Ueki</surname><given-names>S</given-names></name><name><surname>Kikuchi</surname><given-names>Y</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Asano</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mucus plugging in allergic bronchopulmonary aspergillosis: Implication of the eosinophil DNA traps</article-title><source>Allergology international : official journal of the Japanese Society of Allergology</source><year>2018</year><volume>67</volume><issue>2</issue><fpage>280</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">28886913</pub-id></element-citation></ref><ref id="R34"><label>(34)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muniz</surname><given-names>VS</given-names></name><name><surname>Silva</surname><given-names>JC</given-names></name><name><surname>Braga</surname><given-names>YAV</given-names></name><name><surname>Melo</surname><given-names>RCN</given-names></name><name><surname>Ueki</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus</article-title><source>The Journal of allergy and clinical immunology</source><year>2018</year><volume>141</volume><issue>2</issue><fpage>571</fpage><lpage>585</lpage><elocation-id>e7</elocation-id><pub-id pub-id-type="pmid">28943470</pub-id></element-citation></ref><ref id="R35"><label>(35)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruns</surname><given-names>S</given-names></name><name><surname>Kniemeyer</surname><given-names>O</given-names></name><name><surname>Hasenberg</surname><given-names>M</given-names></name><name><surname>Aimanianda</surname><given-names>V</given-names></name><name><surname>Nietzsche</surname><given-names>S</given-names></name><name><surname>Thywissen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA</article-title><source>PLoS pathogens</source><year>2010</year><volume>6</volume><issue>4</issue><elocation-id>e1000873</elocation-id><pub-id pub-id-type="pmcid">PMC2861696</pub-id><pub-id pub-id-type="pmid">20442864</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000873</pub-id></element-citation></ref><ref id="R36"><label>(36)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>OZ</given-names></name><name><surname>Palaniyar</surname><given-names>N</given-names></name></person-group><article-title>NET balancing: a problem in inflammatory lung diseases</article-title><source>Frontiers in immunology</source><year>2013</year><volume>4</volume><fpage>1</fpage><pub-id pub-id-type="pmcid">PMC3553399</pub-id><pub-id pub-id-type="pmid">23355837</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2013.00001</pub-id></element-citation></ref><ref id="R37"><label>(37)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkmann</surname><given-names>V</given-names></name><name><surname>Reichard</surname><given-names>U</given-names></name><name><surname>Goosmann</surname><given-names>C</given-names></name><name><surname>Fauler</surname><given-names>B</given-names></name><name><surname>Uhlemann</surname><given-names>Y</given-names></name><name><surname>Weiss</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps kill bacteria</article-title><source>Science (New York, NY)</source><year>2004</year><volume>303</volume><issue>5663</issue><fpage>1532</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">15001782</pub-id></element-citation></ref><ref id="R38"><label>(38)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>M</given-names></name><name><surname>Lacy</surname><given-names>P</given-names></name><name><surname>Ueki</surname><given-names>S</given-names></name></person-group><article-title>Eosinophil Extracellular Traps and Inflammatory Pathologies-Untangling the Web!</article-title><source>Frontiers in immunology</source><year>2018</year><volume>9</volume><fpage>2763</fpage><pub-id pub-id-type="pmcid">PMC6275237</pub-id><pub-id pub-id-type="pmid">30534130</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2018.02763</pub-id></element-citation></ref><ref id="R39"><label>(39)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>EG</given-names></name><name><surname>Kim</surname><given-names>MN</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><etal/></person-group><article-title>Chitinase 3-Like 1 Contributes to Food Allergy via M2 Macrophage Polarization</article-title><source>Allergy, asthma &amp; immunology research</source><year>2020</year><volume>12</volume><issue>6</issue><fpage>1012</fpage><lpage>1028</lpage><pub-id pub-id-type="pmcid">PMC7492506</pub-id><pub-id pub-id-type="pmid">32935492</pub-id><pub-id pub-id-type="doi">10.4168/aair.2020.12.6.1012</pub-id></element-citation></ref><ref id="R40"><label>(40)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>EJ</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>MN</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>CO</given-names></name><etal/></person-group><article-title>Chitinase 3-like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation</article-title><source>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</source><year>2019</year><volume>49</volume><issue>11</issue><fpage>1464</fpage><lpage>1474</lpage><pub-id pub-id-type="pmid">31397016</pub-id></element-citation></ref><ref id="R41"><label>(41)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Yamauchi</surname><given-names>K</given-names></name><name><surname>Maemondo</surname><given-names>M</given-names></name></person-group><article-title>Role of genetic variations of chitinase 3-like 1 in bronchial asthmatic patients</article-title><source>Clinical and molecular allergy : CMA</source><year>2018</year><volume>16</volume><fpage>9</fpage><lpage>7</lpage><comment>eCollection 2018</comment><pub-id pub-id-type="pmcid">PMC5880007</pub-id><pub-id pub-id-type="pmid">29618952</pub-id><pub-id pub-id-type="doi">10.1186/s12948-018-0086-7</pub-id></element-citation></ref><ref id="R42"><label>(42)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verwer</surname><given-names>PEB</given-names></name><name><surname>ten Kate</surname><given-names>MT</given-names></name><name><surname>Falcone</surname><given-names>FH</given-names></name><name><surname>Morroll</surname><given-names>S</given-names></name><name><surname>Verbrugh</surname><given-names>HA</given-names></name><name><surname>Bakker-Woudenberg</surname><given-names>IAJM</given-names></name><etal/></person-group><article-title>Evidence supporting a role for mammalian chitinases in efficacy of caspofungin against experimental aspergillosis in immunocompromised rats</article-title><source>PloS one</source><year>2013</year><volume>8</volume><issue>10</issue><elocation-id>e75848</elocation-id><pub-id pub-id-type="pmcid">PMC3796522</pub-id><pub-id pub-id-type="pmid">24155872</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0075848</pub-id></element-citation></ref><ref id="R43"><label>(43)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Expression, purification and in vitro antifungal activity of acidic mammalian chitinase against Candida albicans, Aspergillus fumigatus and Trichophyton rubrum strains</article-title><source>Clinical and experimental dermatology</source><year>2009</year><volume>34</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">19076793</pub-id></element-citation></ref><ref id="R44"><label>(44)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>TA</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Tager</surname><given-names>AM</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Voehringer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Chitin induces accumulation in tissue of innate immune cells associated with allergy</article-title><source>Nature</source><year>2007</year><volume>447</volume><issue>7140</issue><fpage>92</fpage><lpage>96</lpage><pub-id pub-id-type="pmcid">PMC2527589</pub-id><pub-id pub-id-type="pmid">17450126</pub-id><pub-id pub-id-type="doi">10.1038/nature05746</pub-id></element-citation></ref><ref id="R45"><label>(45)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dyken</surname><given-names>SJ</given-names></name><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Porter</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Quinlan</surname><given-names>PJ</given-names></name><name><surname>Blanc</surname><given-names>PD</given-names></name><etal/></person-group><article-title>Fungal chitin from asthma-associated home environments induces eosinophilic lung infiltration</article-title><source>Journal of immunology (Baltimore, Md: 1950)</source><year>2011</year><volume>187</volume><issue>5</issue><fpage>2261</fpage><lpage>2267</lpage><pub-id pub-id-type="pmcid">PMC3159725</pub-id><pub-id pub-id-type="pmid">21824866</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1100972</pub-id></element-citation></ref><ref id="R46"><label>(46)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>HR</given-names></name><name><surname>Pirayesh</surname><given-names>A</given-names></name><name><surname>Shahsavan</surname><given-names>S</given-names></name><name><surname>Amani</surname><given-names>S</given-names></name><name><surname>Amini</surname><given-names>SA</given-names></name><name><surname>Samani</surname><given-names>KG</given-names></name><etal/></person-group><article-title>Correlation of acidic mammalian chitinase expression with disease severity in patients with moderate/severe persistent allergic rhinitis</article-title><source>Central-European journal of immunology</source><year>2020</year><volume>45</volume><issue>3</issue><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="pmcid">PMC7790003</pub-id><pub-id pub-id-type="pmid">33437181</pub-id><pub-id pub-id-type="doi">10.5114/ceji.2020.101251</pub-id></element-citation></ref><ref id="R47"><label>(47)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>T</given-names></name><name><surname>Homer</surname><given-names>RJ</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>NY</given-names></name><name><surname>Cohn</surname><given-names>L</given-names></name><etal/></person-group><article-title>Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation</article-title><source>Science (New York, NY)</source><year>2004</year><volume>304</volume><issue>5677</issue><fpage>1678</fpage><lpage>1682</lpage><pub-id pub-id-type="pmid">15192232</pub-id></element-citation></ref><ref id="R48"><label>(48)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>CF</given-names></name><name><surname>Ermert</surname><given-names>D</given-names></name><name><surname>Schmid</surname><given-names>M</given-names></name><name><surname>Abu-Abed</surname><given-names>U</given-names></name><name><surname>Goosmann</surname><given-names>C</given-names></name><name><surname>Nacken</surname><given-names>W</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans</article-title><source>PLoS pathogens</source><year>2009</year><volume>5</volume><issue>10</issue><elocation-id>e1000639</elocation-id><pub-id pub-id-type="pmcid">PMC2763347</pub-id><pub-id pub-id-type="pmid">19876394</pub-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000639</pub-id></element-citation></ref><ref id="R49"><label>(49)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Havelka</surname><given-names>A</given-names></name><name><surname>Sejersen</surname><given-names>K</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name><name><surname>Pauksens</surname><given-names>K</given-names></name><name><surname>Larsson</surname><given-names>A</given-names></name></person-group><article-title>Calprotectin, a new biomarker for diagnosis of acute respiratory infections</article-title><source>Scientific reports</source><year>2020</year><volume>10</volume><issue>1</issue><elocation-id>4208-z</elocation-id><pub-id pub-id-type="pmcid">PMC7060262</pub-id><pub-id pub-id-type="pmid">32144345</pub-id><pub-id pub-id-type="doi">10.1038/s41598-020-61094-z</pub-id></element-citation></ref><ref id="R50"><label>(50)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>LA</given-names></name><name><surname>Gaya</surname><given-names>DR</given-names></name></person-group><article-title>Utility of faecal calprotectin analysis in adult inflammatory bowel disease</article-title><source>World journal of gastroenterology</source><year>2012</year><volume>18</volume><issue>46</issue><fpage>6782</fpage><lpage>6789</lpage><pub-id pub-id-type="pmcid">PMC3520167</pub-id><pub-id pub-id-type="pmid">23239916</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v18.i46.6782</pub-id></element-citation></ref><ref id="R51"><label>(51)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanini</surname><given-names>HF</given-names></name><name><surname>Bernardazzi</surname><given-names>C</given-names></name><name><surname>Castro</surname><given-names>F</given-names></name><name><surname>de Souza</surname><given-names>HSP</given-names></name></person-group><article-title>Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets</article-title><source>World journal of gastroenterology</source><year>2018</year><volume>24</volume><issue>41</issue><fpage>4622</fpage><lpage>4634</lpage><pub-id pub-id-type="pmcid">PMC6224468</pub-id><pub-id pub-id-type="pmid">30416310</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v24.i41.4622</pub-id></element-citation></ref><ref id="R52"><label>(52)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badi</surname><given-names>YE</given-names></name><name><surname>Salcman</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Rana</surname><given-names>B</given-names></name><name><surname>Kermani</surname><given-names>NZ</given-names></name><name><surname>Riley</surname><given-names>JH</given-names></name><etal/></person-group><article-title>IL1RAP expression and the enrichment of IL-33 activation signatures in severe neutrophilic asthma</article-title><source>Allergy</source><year>2023</year><volume>78</volume><issue>1</issue><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="pmcid">PMC10086999</pub-id><pub-id pub-id-type="pmid">35986608</pub-id><pub-id pub-id-type="doi">10.1111/all.15487</pub-id></element-citation></ref><ref id="R53"><label>(53)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Michalec</surname><given-names>L</given-names></name><name><surname>Sripada</surname><given-names>A</given-names></name><name><surname>Gorska</surname><given-names>MM</given-names></name><name><surname>Alam</surname><given-names>R</given-names></name></person-group><article-title>Experimental asthma persists in IL-33 receptor knockout mice because of the emergence of thymic stromal lymphopoietin-driven IL-9(+) and IL-13(+) type 2 innate lymphoid cell subpopulations</article-title><source>The Journal of allergy and clinical immunology</source><year>2018</year><volume>142</volume><issue>3</issue><fpage>793</fpage><lpage>803</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC5945345</pub-id><pub-id pub-id-type="pmid">29132961</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2017.10.020</pub-id></element-citation></ref><ref id="R54"><label>(54)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasetty</surname><given-names>G</given-names></name><name><surname>Jönsson</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>J</given-names></name><name><surname>Grundevik</surname><given-names>P</given-names></name><name><surname>Nys</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>S</given-names></name><etal/></person-group><article-title>IL1RAP is an emerging target in chronic airway inflammatory diseases</article-title><source>European Respiratory Journal</source><year>1948</year><volume>60</volume><issue>suppl 66</issue><pub-id pub-id-type="doi">10.1183/13993003.congress-2022.1948</pub-id></element-citation></ref><ref id="R55"><label>(55)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DE</given-names></name></person-group><article-title>IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma</article-title><source>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</source><year>2010</year><volume>40</volume><issue>2</issue><fpage>200</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">19906013</pub-id></element-citation></ref><ref id="R56"><label>(56)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>BCL</given-names></name><name><surname>Lam</surname><given-names>CWK</given-names></name><name><surname>Tam</surname><given-names>L</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name></person-group><article-title>IL33: Roles in Allergic Inflammation and Therapeutic Perspectives</article-title><source>Frontiers in immunology</source><year>2019</year><volume>10</volume><fpage>364</fpage><pub-id pub-id-type="pmcid">PMC6409346</pub-id><pub-id pub-id-type="pmid">30886621</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00364</pub-id></element-citation></ref><ref id="R57"><label>(57)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griesenauer</surname><given-names>B</given-names></name><name><surname>Paczesny</surname><given-names>S</given-names></name></person-group><article-title>The ST2/IL-33 Axis in Immune Cells during Inflammatory Diseases</article-title><source>Frontiers in immunology</source><year>2017</year><volume>8</volume><fpage>475</fpage><pub-id pub-id-type="pmcid">PMC5402045</pub-id><pub-id pub-id-type="pmid">28484466</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00475</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Author Summary</title></caption><p>Allergic bronchopulmonary aspergillosis (ABPA) is a form of lung disease primarily affecting those with asthma or cystic fibrosis induced by the ubiquitous pathogen <italic>Aspergillus fumigatus</italic>. Understanding the immunological mechanisms contributing to this airway disease is important for the development of novel treatments to improve quality of life and preserve lung function. In this study, we show that an <italic>Aspergillus fumigatus</italic> repeat challenge model phenocopies immunological features of allergic fungal airway disease and is hallmarked by increased IL-1 family signalling. We identify the IL-1RAP as a contributor to eosinophilia and the release of Type 2 cytokines during allergic fungal airway disease. This work represents major step in describing the molecular mechanisms of airway eosinophilia in response to fungal exposure and lays the groundwork for further dissection of inflammatory pathways to target with immunotherapeutic approaches.</p></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><title>Increased inflammation, mucus production and fungal persistence in the lung of mice with allergic fungal airway disease.</title><p><bold>A)</bold> Mice were dosed daily with 2x10<sup>5</sup> live <italic>A. fumigatus</italic> conidia or PBS for 14 days and culled 24 hours after the final dose. Mice were monitored for <bold>B)</bold> survival and <bold>C)</bold> weight change (n=9). <bold>D-G)</bold> Representative lung sections stained for <bold>D)</bold> H&amp;E and <bold>F)</bold> PAS. <bold>E)</bold> %Inflammation and <bold>G)</bold> % Mucus was determined by threshold image analysis. (N=3) <bold>H)</bold> Bronchoalveolar lavage fluid was collected and CFUs were counted (N=4). Data represents mean ± SEM from at least two independent experiments. C) Two-way ANOVA, E, G, H) Students T-test, *P&lt;0.05, **p&lt;0.01. CFU – Colony forming unit, H&amp;E – Hematoxylin &amp; eosin, PAS – Periodic acid Schiff.</p></caption><graphic xlink:href="EMS206422-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>The cellular compartment of the airways changes significantly over the course of chronic exposure to <italic>A. fumigatus</italic>.</title><p>Mice were dosed daily with 2x10<sup>5</sup> live <italic>A. fumigatus</italic> conidia or PBS for up to 14 days and culled 24 hours after the final dose Flow cytometry was carried out to determine the immune cell populations in the airways. <bold>A)</bold> tsne plots representing the airway immune cell composition at 3, 7 and 14 days of <italic>A. fumigatus</italic> exposure. Enumeration of immune cells at 3, 7 and 14 days of <italic>A. fumigatus</italic> exposure for <bold>B)</bold> Eosinophils, <bold>C)</bold> Neutrophils, <bold>D)</bold> Alveolar Macrophages, <bold>E)</bold> Monocytes, <bold>F)</bold> T Cells and <bold>G)</bold> B Cells (N=4-8). Data represents mean ± SEM from at least two independent experiments. B-G) One-way ANOVA, *P&lt;0.05, **P&lt;0.01, ***P&lt;0.001, ****P&lt;0.0001.</p></caption><graphic xlink:href="EMS206422-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Increased damage markers and inflammatory cytokines in the airways of mice with allergic fungal airway disease.</title><p>Mice were dosed daily with 2x10<sup>5</sup> live <italic>A. fumigatus</italic> conidia or PBS for 14 days and culled 24 hours after the final dose. Bulk RNAseq was carried out on bronchoalveolar lavage cells. <bold>A)</bold> Heatmap and <bold>B)</bold> showing all differentially expressed genes (determined as padj&gt;0.05 and fold-change&gt;2) compared to PBS controls. curated list of differentially expressed genes of interest. Dot plot of GO pathway analysis representing the top 10 enriched pathways for <bold>C)</bold> upregulated and <bold>D)</bold> downregulated differentially expressed genes in allergic fungal airway disease <bold>E)</bold> Bar graph showing normalized expression of upregulated interleukins and interleukin receptors in allergic fungal airway disease. E) Students T-test, *P&lt;0.05</p></caption><graphic xlink:href="EMS206422-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Proteomic analysis reveals increased IL-1RAP, IL-1β and IL-33 in allergic fungal airway disease.</title><p>Mice were dosed daily with 2x10<sup>5</sup> live <italic>A. fumigatus</italic> conidia or PBS for 14 days and culled 24 hours after the final dose. Bronchoalveolar lavage fluid was assessed for <bold>A)</bold> LDH (N=8-9) and <bold>B)</bold> Total protein (N=4). <bold>C and D)</bold> LC-MS/MS analysis was carried out on bronchoalveolar lavage fluid to identify differentially expressed proteins (padj&gt;0.05, fold change&gt;2) (N=3) <bold>C)</bold> volcano plot of all identified proteins, <bold>D)</bold> Heat-map of differentially expressed proteins. E<bold>)</bold> Functional protein network association created using STRING software for all 42 differentially expressed proteins, clustered using MCL clustering (&gt;4). Bronchoalveolar lavage fluid was assessed by ELISA for <bold>F)</bold> IL-1β and IL-33 (N=6). Data represents mean ± SEM from at least two independent experiments. A) One-way ANOVA, B, F, G) Students T-test, *P&lt;0.05, ***P&lt;0.001, ****P&lt;0.0001.</p></caption><graphic xlink:href="EMS206422-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>IL-1RAP deficiency reduces eosinophilia during chronic exposure to <italic>A. fumigatus</italic> without loss of fungal control.</title><p>IL1RAP<sup>-/-</sup> and WT mice were dosed daily with or without 2x10<sup>5</sup> live <italic>A. fumigatus</italic> conidia for 14 days and culled 24 hours after the final dose. Mice were monitored for <bold>A)</bold> weight change. <bold>B-H)</bold> Bronchoalveolar lavage fluid (BALF) was collected and assessed for <bold>B)</bold> eosinophil, <bold>C)</bold> alveolar macrophage and <bold>D)</bold> neutrophil counts, <bold>E)</bold> CFUs and levels of <bold>F)</bold> IL-33, <bold>G)</bold> IL-5 and <bold>H)</bold> IL-13 (n=6). Data represents mean ± SEM from at least two independent experiments. A) Two-way ANOVA B-H) Students T-test, *P&lt;0.05, **P&lt;0.01.</p></caption><graphic xlink:href="EMS206422-f005"/></fig></floats-group></article>